Montreal, September 2, 2014. – The President and CEO of CQDM, Diane Gosselin, is pleased to announce the appointment of Mario Chevrette as Vice President, Scientific Affairs effective September 2, 2014. Mr. Chevrette will be responsible for all CQDM scientific affairs. More specifically, he will play a key role in managing funding programs and projects, establishing research partnerships and liaising with CQDM’s pharmaceutical members.
Before joining CQDM, Mario Chevrette was Scientific Director of the Cancer Research Society from 2009 to 2014 and served on the Board of Directors and the Executive Committee in various other capacities, namely as Chairman of the Board from 2003 to 2011. In 1990, he served as Assistant Professor in the Department of Biochemistry at the University of Ottawa before joining the Departments of Urology and Oncology at McGill University in Montreal in 1995. Mario Chevrette holds a Ph.D. in molecular and cellular biology from Université Laval. He was a postdoctoral fellow from 1986 to 1990, first at the University of Southern California in Los Angeles and then at the Center for Cancer Research Fred Hutchinson in Seattle.
“It is with great enthusiasm that we welcome Mario to the team. His proven expertise in program management and scientific partnerships will certainly be an asset for our organisation. Mario will play a key role in developing CQDM’s scientific affairsas well as contributing to further develop CQDM’s notoriety,” said Ms. Gosselin.
CQDM is a pharma-based consortium active in pre-competitive research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. CQDM receives financial support from AstraZeneca, Merck, Pfizer Canada, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Novartis Pharma Canada, Sanofi Canada, as well as from Quebec’s Ministry of Economy, Innovation and Exports (MEIE) and under the Federal government’s Business-Led Networks of Centres of Excellence Program (BL-NCE).For more information, visit us at www.cqdm.org.